Aeromics
Cleveland
About Aeromics
Aeromics is a clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke. A paradigm shift in its understanding of water physiology was the discovery aquaporins, proteins that form water channels to allow water into and out of cells, by Peter Agre (2003 Nobel Prize in Chemistry). Despite the vital role of aquaporins in maintaining water homeostasis and its implications in various disease states, therapeutic agents targeting aquaporins have until now remained elusive. Aeromics’ drug candidate, AER-271, targets aquaporin-4 (AQP4), the primary water channel in the brain, and has best-in-class credentials for acute intravenous therapy for stroke-related cerebral edema (CE).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $12.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2017)
- Website: aeromics.com
- Phone: 216-772-1004
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aeromics-62715 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.